EGFR Mutations in Lung Adenocarcinomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EGFR Mutations in Lung Adenocarcinomas

Published:2008-05 Issue:3 Volume:10 Page:242-248
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Li Allan R.,Chitale Dhananjay,Riely Gregory J.,Pao William,Miller Vincent A.,Zakowski Maureen F.,Rusch Valerie,Kris Mark G.,Ladanyi Marc

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference25 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. EGF receptor gene mutations are common in lung cancers from “never smokers” and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva);Pao;Proc Natl Acad Sci USA,2004

4. Rapid PCR-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas;Pan;J Mol Diagn,2005

5. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers;Shigematsu;J Natl Cancer Inst,2005

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrochemical sensing technology based on a ligation-initiated LAMP-assisted CRISPR/Cas12a system for high-specificity detection of EGFR E746–A750 deletion mutation;Biosensors and Bioelectronics;2024-11

2. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

3. Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway;Bioorganic Chemistry;2024-09

4. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants;Nature Communications;2024-03-28

5. HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors;Translational Lung Cancer Research;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3